BINIMETINIB TABLETS 15 MG
Binimetinib is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation
Note: Products are not marketed in countries where it is protected by Patent Law
Enter your name and email to download PDF.
Thanks, I’m not interested